The role of radiotherapy and chemotherapy for curative management of medically inoperable and stage III nonsmall cell lung cancer, and radiotherapy for palliation of symptomatic disease

Respiratory Care Clinics of North America

Volumn 9, Issue 2, 2003, Pages 163-190

  Turrisi III, Andrew T ^a   Bogart, Jeffrey ^b   Sherman, Carol ^c   Silvestri, Gerard ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; GEFITINIB; GEMCITABINE; LOMUSTINE; METHOTREXATE; MITOMYCIN; NARCOTIC ANALGESIC AGENT; NAVELBINE; PACLITAXEL; RADIOSENSITIZING AGENT; STEROID; VINBLASTINE; VINDESINE;

BONE METASTASIS; BONE PAIN; BRAIN METASTASIS; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DOSE RESPONSE; DOSIMETRY; ESOPHAGITIS; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MULTIMODALITY CANCER THERAPY; PNEUMONIA; RADIOSURGERY; REVIEW; STEREOTAXIC SURGERY; SURVIVAL RATE; SYMPTOMATOLOGY; THREE DIMENSIONAL IMAGING; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0038543319     PISSN: 10785337     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5337(02)00087-4     Document Type: Review

References (95)

1. Yancik R. Cancer burden in the aged. Cancer 1997;80:1273-83.
2. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7.
3. Havlik RJ, Yancik R, Long S, et al. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994;74(Suppl):2102-6.
4. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99-105.
5. Dosoretz DE, Katin MJ, Blitzer PH, et al. Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys 1992;24:3-9.
6. Dupuy DE, Zagoria RJ, Akerley W, et al. Percutaneous radiofrequency ablation of malignancies in the lung. Am J Roentgenol 2000;174:57-9.
7. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surgery 19950:622-3.
8. Errett LE, Wilson J, Chin RC, et al. Wedge resection as an alternative procedure for peripheral bronchogenic carcinoma in poor-risk patients. J Thorac Cardiovasc Surg 1985;90(5):656-61.
9. Temeck BK, Schafer PW, Saini N. Wedge resection for bronchogenic carcinoma in high-risk patients. South Med J 1992;85:1081-3.
10. Miller JI, Hatcher CR. Limited resection of bronchogenic carcinoma in the patient with marked impairment of pulmonary function. Ann Thorac Surg 1987;44:340-3.
11. Mentzer SJ, DeCamp MM, Harpole DH Jr. et al. Thoracoscopy and video-assisted thoracic surgery in the treatment of lung cancer. Chest 1995;107(Suppl):S298S-S301S.
12. Bogart J, Shennib H, Kohman L, et al. Postoperative radiotherapy following thorascopic wedge resection of T1 non-small cell lung cancer in high risk patients: A Cancer and Leukemia Group B and Eastern Cooperative Oncology Group Phase II Trial. Proc Am Soc Clin Oncol 2000;19:48a.
13. Shennib H, Bogart JA, Herndon J, et al. Thorascopic wedge resection and radiotherapy for T1N0 non-small cell lung cancer (NSCLC) in high risk patients: preliminary analysis of a Cancer and Leukemia Group B and Eastern Cooperative Oncology Group phase II trial [abstract]. Int J Radiat Oncol Biol Phys 2000;48(Suppl):232.
14. Gauden S, Ramsay J, Tripcony L. The curative treatment by radiotherapy alone of Stage I nonsmall cell carcinoma of the lung. Chest 1995;108:1278-82.
15. Sibley GS. Radiotherapy for patients with medically inoperable Stage I nonsmall cell lung carcinoma. Cancer 1998;82:433-8.
16. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax 2001;56:628-38.
17. Bentzen SM, Saunders MI, Dische S, et al. Updated data for CHART in NSCLC: further analyses. Radiother Oncol 2000;55:86-7.
18. Graham PH, Gebski VJ, Langlands AO. Radical radiotherapy for early stage nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1995;31:261-6.
19. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiotherapy alone for clinical stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1997;38:521-5.
20. Krol A, Aussems P, Noordijk EM, et al. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation. Int J Radiat Oncol Biol Phys 1996;34:297-302.
21. Morita K, Kuwa N, Suzuki Y, et al. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients. Radiother Oncol 1997;42:31-6.
22. Slotman BJ, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother Oncol 1996;41:41-4.
23. Zhang HX, Yin WB, Zhang LJ, et al. Curative radiotherapy of early operable non-small cell lung cancer. Radiother Oncol 1989;14:89-94.
24. Abratt RP. Modelling tumour and treated lung volume influences in the irradiation of non-small cell lung cancer patients. Int J Radiat Oncol Biol Phys 2001;49:481-5.
25. Graham MV, Purdy JA, Harms W, et al. Survival and prognostic factors of non-small cell lung cancer (NSCLC) patients treated with definitive three-dimensional (3D) radiation therapy. Int J Radiat Oncol Biol Phys 1998;42(Suppl):166.
26. Martel MK, Strawderman M, Hazuka MB, et al. Volume and dose parameters for survival of non-small cell cancer patients. Radiother Oncol 1997;44(1):23-9.
27. Willner J, Caragiani E, Tschammler A, et al. The influence of total dose and tumor volume on local control and survival in non small cell lung cancer [abstract]. Int J Radiat Oncol Biol Phys 2000;48(Suppl):327.
28. Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002;52:49-57.
29. Rosenzweig KE, Dladla N, Schindelheim R, et al. Three-dimensional conformal radiation therapy (3D-CRT) for early-stage non-small-cell lung cancer. Clin Lung Cancer 2001; 3:141-4.
30. Henning GT, Littles JF, Martel ML, et al. Preliminary results of 92.4 Gy or more for non-small cell lung cancer [abstract]. Int J Radiat Oncol Biol Phys 2002;48(Suppl):233.
31. Graham MV, Winter K, Purdy JA, et al. Preliminary results of a Radiation Therapy Oncology Group trial (RTOG 9311), a dose escalation study using 3D conformal radiation therapy in patients with inoperable nonsmall cell lung cancer [abstract]. Int J Radiat Oncol Biol Phys 2001;51(Suppl 1):19-20.
32. Maguire PD, Marks LB, Sibley GS, et al. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non small-cell lung cancer. J Clin Oncol 2001;19:705-11.
33. Belderbos JS, De Jaeger K, Heemsbergen WD, et al. Interim analysis of a phase I/II dose escalation trial in non-small cell lung cancer (NSCLC) using three-dimensional conformal radiotherapy (3D-CRT) [abstract]. Int J Radiat Oncol Biol Phys 2001;51(Suppl 1):345-6.
34. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27(2):131-46.
35. Mehta M, Scrimger R, Mackie R, et al. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;49(1):23-33.
36. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997;350(9072): 161-5.
37. Mountain CF, Libshitz HI, Hermes KE. Lung cancer handbook for staging and imaging. 3rd edition. Houston: Clifton F. Mountain Foundation; 1996.
38. Noordijk EM, Clement E, Hermans J, et al. Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol 1988;13:83-9.
39. Nagata Y, Negoro T, Aoki T, et al. Clinical outcomes of 3-D conformal hypofractionated single high dose radiotherapy for one or two lung tumors using a stereotactic body frame [abstract]. Int J Radiat Oncol Biol Phys 2001;51(Suppl 1):352-3.
40. Onimaru R, Shirato H, Shimizul S, et al. Tumor control and respiratory function after stereotactic irradiation (STI) for primary and metastatic lung cancer [abstract 2231]. Int J Radiat Oncol Biol Phys 2001;51(Suppl 1):345.
41. Uematsu MD, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small-cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001;51:666-70.
42. Lyman JT, Wolbarst AB. Optimization of radiation therapy, III: a method of assessing complication probabilities from dose-volume histograms. Int J Radiat Oncol Biol Phys 1987;13(1):103-9.
43. Kutcher GJ, Burman C, Brewster L, et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys 1991;21:137-46.
44. Armstrong J, Raben A, Zelefsky M, et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 1997;44: 17-22.
45. Mah D, Hanley J, Rosenzweig KE, et al. Technical aspects of the deep inspiration breath-hold technique in the treatment of thoracic cancer. Int J Radiat Oncol Biol Phys 2000; 48(4):1175-85.
46. Kong F, Jirtle RL, Huang DH, et al. Plasma transforming growth factor-B1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999;86:1712-9.
47. Green N, Weinstein H. Reassessment of radiation therapy for the management of lung cancer in patients with chronic pulmonary disease. Int J Radiat Oncol Biol Phys 1983; 9:1891-6.
48. Sugi K, Nawata K, Fujita N, et al. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter. World J Surg 1998;22(3):290 4.
49. Sawyer TE, Bonner JA, Gould PM, et al. Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: implications related to the design of clinical trials. Int J Radiat Oncol Biol Phys 1999; 45(2):315-21.
50. Liengswangwong V, Bonner JA. Point: the potential importance of elective nodal irradiation in the treatment of non-small cell lung cancer. Semin Radiat Oncol 2000; 10(4):308-14.
51. Williams TE, Thomas CR Jr, Turrisi AT III. Counterpoint: better radiation treatment of non-small cell lung cancer using new techniques without elective nodal irradiation. Semin Radiat Oncol 2000;10(4):315-23.
52. Sibley GS, Jamieson TA, Marks LB, et al. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 1998;40(1):149-54.
53. Rosenzweig KE, Sim SE, Mychalczak B, et al. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2001;50(3):681-5.
54. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001;19:127-36.
55. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999;213(2):530-6.
56. Shimizu S, Shirato H, Kagei K, et al. Impact of respiratory movement on the computed tomographic images of small lung tumors in three-dimensional (3D) radiotherapy. Int J Radiat Oncol Biol Phys 2000;46(5):1127-33.
57. Giraud P, De Rycke Y, Dubray B, et al. Conformal radiotherapy (CRT) planning for lung cancer: analysis of intrathoracic organ motion during extreme phases of breathing. Int J Radiat Oncol Biol Phys 2001;51(4):1081-92.
58. Ramsey CR, Scaperoth D, Arwood D, et al. Clinical efficacy of respiratory gated conformal radiation therapy. Med Dosim 1999;24(2):115-9.
59. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6(4):633-41.
60. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
61. Schiller JH, Harringon D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;345(2):92-8.
62. Langendijk JA, Aaaronson NK, de Jong JMA, et al. Prospective study on quality of life before and after radical radiotherapy in non-small cell lung cancer. J Clin Oncol 2001;19:2123-33.
63. Johnson DH, Einhorn LH, Bartolucci A, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990;113:33-8.
64. Kubota K, Furuse K, Kawahara M, et al. Role of radiotherapy in combined modality treatment of locally advanced non-small cell lung cancer. J Clin Oncol 1994;12: 1547-52.
65. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III non-small cell lung cancer. N Engl J Med 1990;323:940-5.
66. Dillmann R, Herndon J, Seagren S, et al. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B(CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-5.
67. Sause W, Kolesar P, Taylor S IV, et al. Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-64.
68. Morton RF, Jett JR, McGinnis WE, et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized Phase III trial. Ann Int Med 1991;115:681-6.
69. Brodin O, Nou E, Mercke C, et al. Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. Eur J Cancer 1996;32:1893-900.
70. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone vs. combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer. A meta-analysis. Cancer 1995;76:593-601.
71. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer. Ann Intern Med 1996;125:723-9.
72. Buccheri G, Ferrigno D. Therapeutic options for regionally advanced non-small cell lung cancer. Lung Cancer 1996;14:281-300.
73. Schaake-Koning C, van den Bogaert W, Dalesio O. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992;326:524-30.
74. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in resectable stage III non-small cell lung cancer. J Clin Oncol 1999;17:2692-9.
75. Curran WJ, Scott C, Langer C, et al. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410 [abstract]. Proc Am Soc Clin Oncol 2000;19:484a.
76. Komaki R, Seiferheld W, Curran W, et al. Sequential versus concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a Phase III study (RTOG 9410). Int J Radiat Oncol Biol Phys 2000;48:5.
77. Vokes EE, Leopold KA, Herndon JE II, et al. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB Study 9431) [abstract]. Proc Am Soc Clin One 1999;18:459a.
78. Akerley W, Herndon J, Turrisi A, et al. Induction chemotherapy with paclitaxel (P) and carboplatin (C) followed by concurrent thoracic radiation and weekly PC for patients with unresectable stage III non-small cell lung cancer (NSCLC): preliminary analysis of a Phase II trial by the Cancer and Leukemia Group B [abstract]. Proc Am Soc Clin Oncol 2000;19:490a.
79. Albain KS, Crowley JJ. Turrisi AT III, et al. Concurrent cisplatin/etoposide plus radiotherapy (PE + RT) for pathologic stage (path TN) IIIB non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) phase II study (S9019) [abstract]. Proc Am Soc Clin Oncol 1997;16:446a.
80. Gandara DR, Lovato LC, Albain KS, et al. Prolonged survival in pathologic stage IIIB non-small cell lung cancer (NSCLC) with concurrent chemoradiotherapy followed by consolidation docetaxel: a phase II study (S9504) of the Southwest Oncology Group (SWOG) [abstract]. Proc Am Soc Clin Oncol 2000;19:490a.
81. Gaspar L, Gandara D, Chansky K, et al. Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIb non-small cell lung cancer (NSCLC) (SWOG 9504): patterns of failure and updated survival [abstract]. Proc Am Soc Clin Oncol 2001;20:315a.
82. Kelly K. Management of inoperable advanced non-small-cell lung cancer: a Southwest Oncology Group approach. Advances in Lung Cancer 2001;3(2):3-5.
83. Simpson JR, Francis ME, Perez-Tamkayo R, et al. Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial. Int J Radiat Oncol Biol Phys 1985;11:751-8.
84. Slawson RG, Salazar OM, Poussin-Rosillo H, et al. Once-a-week vs conventional daily radiation treatment for lung cancer: final report. Int J Radiat Oncol Biol Phys 1988;15: 61-8.
85. Teo P, Tai TH, Choy D, et al. A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1988;14: 867-71.
86. Cancer (NSCLC). A medical research council randomized trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 1991;63:265-70.
87. Medical Research Council Lung Cancer Working Party. A medical research council (MRC) randomized trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br J Cancer 1992;65:934-41.
88. Medical Research Council Lung Cancer Working Party. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable Medical Research Council Lung Cancer Working Party. Inoperable non-small cell lung cancer and good performance status. Clin Oncol 1996;8:167-75.
89. Abratt RP, Sherpherd LJ, Mameena Salton DG. Palliative radiation for stage 3 non-small cell lung cancer - a progressive study of two moderately high dose regimens. Lung Cancer 1995;13:137-43.
90. Sullivan FJ. Palliative radiotherapy for lung cancer. In: Pass HI, editor. Lung cancer principles and practice. Philadelphia: Lippincott-Raven; 1996.
91. Smith JA Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989;141:85-7.
92. Serafini AN, Houston SJ, Resche I. Palliation of pain associated with metastatic bone cancer using samaruim-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16(4):1574-81.
93. Grauer A, Ziegler R. Bisphosphonate therapy in the management of skeletal metastases. Orthopade 1998;27:231-9.
94. Coleman RE, Purohit OP, Vinholes JJ. High Dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 1997;80(Suppl):1686-90.
95. Wright DC, Delaney TF, Buckner JC. Treatment of metastatic cancer to the brain. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology, vol. 4. Philadelphia: J B Lipincott; 1993.